AnaCardio is a privately held clinical stage biopharmaceutical company developing novel drugs to treat heart failure.
AnaCardio has raised €14M across 1 funding round from 5 investors, most recently a Series A round in Sep 2022. Based in Stockholm, Sweden; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-09-09 | Series A | €14M |
| 3B Health Ventures,Flerie Invest,Fredrik and Ann-Helene Ljungström,Industrifonden,Karolinska Development |
| View deal → |
